“Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS” – Talon pharmaceuticals

In Research in 2016 by ARSACS

The overall objective of the project is to devel+op TPS-100 as a first treatment of ARSACS and to identify a second generation drug based on efficacy and knowledge of receptor pharmacology of TPS-100. Our goal is to synthesize a directed library of compounds with varying Kv channel pharmacology with the goal of enhancing activity at Kv1.2, 1.3, 1.4 relative to Kv1.5 and Kv1.1 which are believed to be associated with potential side effects (Table 2).

Duration: one year
Grant: $100,000
Shawn Maddaford, Talon Pharmaceutical Services Inc.
2660 Speakman Drive, Rm A-61 Mississauga, ON L5K 2L1
Tel:(416) 479-0738 ext 102

Interesting, right? Share with your friends & followers / Intéressant, non? Partagez avec vos amis: